|
|
News Breaks | | | | September 4, 2012 | | 12:16 EDT |  | SNTS, PRX | Appeals court finds parts of Santarus patents valid
A federal appeals court earlier today overturned a ruling by a lower court which held that patents obtained by Santarus (SNTS) for a stomach acid treatment were all invalid. Ruling on the validity of an attempt by Par Pharmaceuticals (PRX) to market a generic version of Santarus' gastric acid treatment Zegerid, the district court found that Santarus' patents were invalid because they were based on obvious ideas. However, the appeals court found that parts of two of Santarus' patents were not based on obvious concepts, and it ordered the lower court to reconsider its verdict based on its findings. In early afternoon trading, Santarus rose 3.4% to $6.39 before being halted, while Par added 0.16% to $49.88. | |
|
News For SNTS;PRX From The Last 14 Days Check below for free stories on SNTS;PRX the last two weeks. |
|
|
| June 18, 2013 | | 05:30 EDT | | SNTS | Santarus, Pharming Group announce FDA acceptance for review of Ruconest BLA
 Subscribe for More Information | | | June 13, 2013 | | 08:24 EDT |  | SNTS | Santarus price increases positive, says Roth Capital
Subscribe for More Information | | | June 10, 2013 | | 07:14 EDT | | SNTS | Santarus checks positive, says Stifel
After surveying 30 gastroenterologists last month, Stifel reports that the doctors were very satisfied with Santarus' Uceris, an ulcerated colitis treatment. Moreover, more than 50% of the doctors said they were comfortable proscribing the drug for off-label conditions, the firm stated. Stifel keeps a Buy rating on the shares. | |
|
|
|
|
|
|
